TB-500 is the name used in the research supply market for a synthetic peptide derived from thymosin beta-4, a 43-residue actin-binding protein found in most mammalian cells. Laboratory studies of thymosin beta-4 and its fragments examine actin dynamics, cell migration and tissue-repair signalling in cell culture and animal models. Because the name TB-500 is applied to more than one molecule, identity matters as much as biology. This article summarises the structure, proposed mechanism, published research areas and the analytical and storage standards needed for reproducible work. It is written for laboratory researchers and offers no guidance on human use.
What is TB-500?
TB-500 is not a recognised pharmacopoeial or chemical name. In supplier catalogues it is used loosely for synthetic material related to thymosin beta-4 (Tβ4), and two distinct things are sold under the label. The first is the short active-region fragment, most often described as the acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (residues 17 to 23 of Tβ4), with a molecular weight of about 889 Da. The second is a full-length synthetic copy of the 43-residue protein, which is about 4963 Da. These are very different test articles, and results obtained with one cannot be assumed to apply to the other.
Native thymosin beta-4 has the sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. It is N-terminally acetylated, highly acidic and intrinsically disordered in solution, taking on structure when it binds actin. It was first isolated in the early 1980s from thymosin fraction 5, a crude calf thymus extract studied by Allan Goldstein and colleagues, and was initially considered a thymic hormone. Later work showed that it is widely expressed and is the major actin-sequestering peptide in many cell types, which redirected research towards cytoskeletal biology.
The region that matters most for actin binding is the central motif LKKTET, residues 17 to 22. That is the reason the short fragment is studied. Whether a synthetic fragment reproduces the full range of activities reported for the parent protein is a question the supplier literature rarely addresses, and the published work on the protein cannot be borrowed for the fragment without caution.
Regulatory context matters for any UK buyer. TB-500 is not authorised as a medicine in the United Kingdom, and thymosin beta-4 and related compounds appear on the World Anti-Doping Agency prohibited list. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings about unlicensed products marketed for human use. The material is relevant here only as a laboratory research reagent.
Mechanism of action
The best-established function of thymosin beta-4 is the regulation of actin. Cells maintain a pool of monomeric globular actin (G-actin) that polymerises into filaments (F-actin) to form the cytoskeleton, and the balance between the two shapes cell shape, motility and division. Tβ4 binds G-actin in a one-to-one complex through its LKKTET region and prevents it from joining filaments, which makes it a buffer that holds a reservoir of polymerisable actin. The complex can release actin when it is needed, for instance at the leading edge of a migrating cell, in coordination with proteins such as profilin.
Because actin dynamics govern migration, this mechanism connects the peptide to cell motility in culture. Reports describe changes in the migration of endothelial cells, keratinocytes and other cell types in the presence of Tβ4, usually measured in scratch assays or transwell assays. The effect of a fragment in the same assays depends on whether it retains sufficient actin affinity, which should be tested and not assumed.
A second line of work concerns extracellular and intracellular signalling roles. Reports from several groups describe Tβ4 effects on integrin-linked kinase, the Akt survival pathway and the expression of angiogenic and inflammatory mediators in some systems. These findings are less settled than the actin mechanism. Receptor-mediated actions have been proposed, but a dedicated cell-surface receptor has not been conclusively established, and some extracellular effects may relate to the peptide’s interactions with other proteins.
For laboratory design, two practical points follow. The first is that the intracellular actin-binding mechanism requires the peptide to be inside the cell, whereas peptides applied to culture medium may act through different routes, so the system and the interpretation need to be matched. The second is that, in cell-based work, “dosage” means molar concentration in the medium, which depends on net peptide content, adsorption to plasticware and protease activity in any serum used. Controls with a scrambled sequence or an inactive fragment help to separate specific effects from artefacts.
What the research shows
The literature on thymosin beta-4 is substantial, but the literature on the supply-market fragment is much thinner. Four areas of work are summarised below in general terms. Readers should consult the primary papers for methods, concentrations and statistics, because commercial summaries often overstate findings.
The first area is the biochemistry of actin sequestration. Work published in the early 1990s showed that Tβ4 forms a one-to-one complex with G-actin and reduces the pool available for polymerisation, and structural studies later described how the peptide wraps around the actin monomer. These experiments used purified proteins and cell extracts, and they establish the core mechanism. The literature can be explored through a PubMed search on thymosin beta-4 actin sequestration.
The second area is animal wound models. A 1999 paper by Malinda and colleagues in the Journal of Investigative Dermatology reported that Tβ4 applied to full-thickness wounds in rats was associated with faster re-epithelialisation and increased collagen deposition compared with controls, and that it stimulated keratinocyte migration in a transwell assay. Exposures were expressed as microgram quantities per wound or per animal and differ with route, so they should be taken from the primary paper. This was a controlled rat experiment under ethical approval, and it is described only as part of the scientific record. It can be located through a PubMed search on thymosin beta-4 and rat dermal wound healing.
The third area is cardiac biology in mice. A 2004 paper in Nature by Bock-Marquette and colleagues reported that Tβ4 promoted cardiomyocyte migration and survival in culture and, in a mouse model of experimental coronary artery ligation, was associated with improved survival of cardiac cells and altered scar formation. The mechanism proposed involved integrin-linked kinase and Akt signalling. This is a rodent finding and carries no implication for people. It is also an example of how the same protein is studied across very different contexts.
The fourth area is the fragment itself. A smaller set of studies has examined short Tβ4-derived peptides, including the LKKTET-containing sequence, for actin binding and for effects in cell migration and angiogenesis assays. Findings are mixed, and some studies reported that fragments retain only part of the activity of the full protein. Because of this, results from the full-length protein should not be read across to the heptapeptide.
A recurring limitation runs through this body of work. Much of the animal literature concerns recombinant or synthetic full-length Tβ4 and not the fragment sold as TB-500, exposures and routes differ between groups, and the exact material used is not always characterised analytically. Reproducibility therefore depends on knowing exactly what was in the vial.
Research applications
In the laboratory, thymosin beta-4 and its fragments are used in several contexts. The most common is cell biology of the cytoskeleton, where the peptide serves as a tool for perturbing the G-actin pool and studying how actin dynamics affect shape, migration and division. Scratch assays, transwell migration assays and live-cell imaging of actin are typical readouts.
A second context is wound-repair and angiogenesis models in cell culture, using keratinocytes, fibroblasts and endothelial cells, often with tube-formation assays. These are used to probe how cytoskeletal regulation interacts with growth factor signalling, with the peptide compared against vehicle and inactive-sequence controls.
A third context is protein biochemistry and structural biology. Tβ4 is an intrinsically disordered protein that folds on binding, which makes it a standard example for studies of disorder-to-order transitions, and actin-binding peptides are used in biophysical assays such as fluorescence anisotropy and isothermal titration calorimetry.
A fourth context is analytical and anti-doping science. Because thymosin beta-4 and related compounds are on the World Anti-Doping Agency prohibited list, reference material of defined identity and purity is used to develop and validate liquid chromatography and mass spectrometry methods for their detection. For this purpose, accurate mass and quantified purity are essential.
Work involving animals in the United Kingdom requires institutional ethical review and authorisation under the Animals (Scientific Procedures) Act 1986. Research peptides are not authorised medicines for human or veterinary use.
Purity, storage and handling
Peptide purity is assessed by reversed-phase high-performance liquid chromatography (HPLC) with UV detection at 214 or 220 nm, where the peptide bond absorbs. The two forms sold as TB-500 pose different problems. The short heptapeptide is small and polar, so it may elute early and impurities can be hard to resolve, and the N-terminal acetyl group is a modification that must be confirmed. The full-length 43-residue protein is demanding to synthesise, and deletion and truncation products are likely to be more numerous. In both cases, a stated purity is meaningful only if the method and chromatogram are available.
HPLC must be paired with mass spectrometry. The expected mass is about 889 Da for Ac-LKKTETQ and about 4963 Da for full-length Tβ4. A mass about 42 Da lower than expected would suggest a missing acetyl group, and a mass about 16 Da higher indicates oxidation, which affects the methionine in the full-length sequence. A clean peak at the wrong mass is a clean peak of the wrong compound, and this is the central reason that a certificate of analysis must state which TB-500 the vial contains.
A batch-specific certificate of analysis matters because purity, peptide content and the degree of acetylation can differ between synthesis runs. It should carry a lot number matching the vial, the HPLC result, the observed and theoretical masses, the test date and, ideally, the salt form and net peptide content. Lyophilised powders contain counterions and residual water, so the weighed mass is not the mass of peptide, and ignoring this introduces systematic errors into any concentration-response comparison.
Because degradation accelerates once the peptide is in solution, and because the glutamine and glutamate residues are susceptible to cyclisation and deamidation, batch-level verification matters more here than with robust small molecules. UK laboratories sourcing Tb 500 should expect a batch-specific certificate of analysis that states the exact form and mass, with lyophilised storage at -20°C, and the same documentation standard applies when weighing any best peptides supplier uk claim, since a supplier’s analytical record rather than its search ranking shows whether the vial matches its stated specification.
Lyophilised TB-500 is generally stored at -20°C in a sealed container with desiccant, and many laboratories use -80°C for long-term archives. Vials should reach room temperature before opening so that condensation does not form on the cold powder. After reconstitution, stability falls. Standard practice is to dissolve the peptide in sterile water or a suitable buffer, divide the solution into single-use aliquots and freeze them to avoid repeated freeze-thaw cycles. Refrigerated storage at 2 to 8°C is sometimes used for solutions consumed within days, but the acceptable period should be validated for the assay concerned, preferably by re-running HPLC on stored solution. An N-terminal glutamine or glutamate-rich sequence can cyclise or deamidate at neutral to alkaline pH.
Light sensitivity is a secondary concern, since the heptapeptide contains no aromatic residues, but amber vials or dark storage remain good practice, particularly for the full-length protein, which contains phenylalanine and methionine. Peptides also adsorb to glass and some plastics at low concentrations, so low-bind tubes are preferred for dilute working solutions.
Labelling is a final indicator of quality. Clear naming that distinguishes the fragment from the full-length protein, with sequence, molecular weight, lot number, salt form and an unambiguous research-only statement, suggests a supplier that understands its market. Wording that implies use in humans is a warning sign and raises regulatory concerns in the United Kingdom.
Frequently asked questions
What is TB-500 used for in laboratory research?
It is used as a tool in cell biology of the actin cytoskeleton, in migration and angiogenesis assays, and as a reference material in anti-doping analytical methods. It is a research reagent for in-vitro and approved animal work, and it is not an authorised medicine in the United Kingdom.
Is TB-500 the same as thymosin beta-4?
Not necessarily. Thymosin beta-4 is a 43-residue protein of about 4963 Da. The name TB-500 is applied by suppliers either to a short fragment such as Ac-LKKTETQ (about 889 Da) or to a full-length copy. The certificate of analysis should state which one is supplied.
How should TB-500 be stored for research?
Keep lyophilised peptide at -20°C, or -80°C for long-term archiving, in a sealed, dry, light-protected container. Allow vials to reach room temperature before opening. After reconstitution, aliquot and freeze the solution to avoid repeated freeze-thaw cycles and prolonged storage in solution.
How can I verify the quality of a TB-500 batch?
Request a batch-specific certificate showing HPLC purity and a mass spectrometry result matching the stated form, near 889 Da for the fragment or 4963 Da for the full protein, with a lot number matching the vial. For critical work, independent testing by an accredited laboratory confirms identity and purity.
TB-500 is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
Research material from Peptides Lab UK: TB-500 for laboratory research (UK dispatch, batch certificate of analysis, research use only).
